Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Uterine Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Cervical Cancer (106
)
Cervical Cancer (106
)
›
Associations
(208)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
KRAS G12D
Endometrial Cancer
KRAS G12D
Endometrial Cancer
trametinib + BI-3406
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
trametinib + BI-3406
Sensitive
:
D
AACR 2023 - 1wk
trametinib + BI-3406
Sensitive: D – Preclinical
AACR 2023 - 1 week
trametinib + BI-3406
Sensitive
:
D
AACR 2023 - 1 week - (New D)
CLDN6 expression
Endometrial Cancer
CLDN6 expression
Endometrial Cancer
CTIM-76
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
CTIM-76
Sensitive
:
D
AACR 2023 - 1wk
CTIM-76
Sensitive: D – Preclinical
AACR 2023 - 1 week
CTIM-76
Sensitive
:
D
AACR 2023 - 1 week - (New D)
CLDN18.2 expression
Endometrial Cancer
CLDN18.2 expression
Endometrial Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks (New D)
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 2wk
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
Clin Cancer Res - 2 weeks - (New D)
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
HER-2 expression
Endometrial Adenocarcinoma
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
NTRK1 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
NTRK2 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin + paclitaxel + SGN-15
Sensitive: A2 - Guideline
cisplatin + paclitaxel + SGN-15
Sensitive
:
A2
cisplatin + paclitaxel + SGN-15
Sensitive: A2 - Guideline
cisplatin + paclitaxel + SGN-15
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
HER-2 positive
Endometrial Cancer
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
TMB-H
Endometrial Cancer
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin + ifosfamide
Sensitive: A2 - Guideline
cisplatin + ifosfamide
Sensitive
:
A2
cisplatin + ifosfamide
Sensitive: A2 - Guideline
cisplatin + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
paclitaxel + ifosfamide
Sensitive
:
A2
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
paclitaxel + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
ifosfamide
Sensitive: A2 - Guideline
ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin + SGN-15
Sensitive: A2 - Guideline
cisplatin + SGN-15
Sensitive
:
A2
cisplatin + SGN-15
Sensitive: A2 - Guideline
cisplatin + SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
SGN-15
Sensitive: A2 - Guideline
SGN-15
Sensitive
:
A2
SGN-15
Sensitive: A2 - Guideline
SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
temsirolimus
Sensitive: A2 - Guideline
temsirolimus
Sensitive
:
A2
temsirolimus
Sensitive: A2 - Guideline
temsirolimus
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
NTRK3 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
NTRK2 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
tamoxifen + medroxyprogesterone
Sensitive: A2 - Guideline
tamoxifen + medroxyprogesterone
Sensitive
:
A2
tamoxifen + medroxyprogesterone
Sensitive: A2 - Guideline
tamoxifen + medroxyprogesterone
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login